What are the opening hours?

Monday 8:30am - 5pm Tuesday 8:30am - 5pm Wednesday 8:30am - 5pm Thursday 8:30am - 5pm Friday 8:30am - 5pm

Rodrigo Arrangoiz MS, MD, FACS, FSSO

Home
United States
Miami Beach, FL
Rodrigo Arrangoiz MS, MD, FACS, FSSO

Assistant Professor at the Columbia University Division of Surgical Oncology at Mount Sinai Medical Center

Surgical Excellence / Excelencia Quirúrgica

02/18/2026

The 19th St. Gallen international breast cancer conference ‘primary therapy of patients with early breast cancer. Evidence, controversies, consensus’: key moments and breakthroughs

Conference OverviewHeld March 12–15, 2025 in Vienna with >3,100 global participants.Focused on early breast cancer (BC): evidence, controversies, consensus, and breakthroughs.Included lectures, …

02/14/2026

Drains in Thyroid Surgery

Paper summary (Eur Arch Otorhinolaryngol, 2026) — “The impact of drains on surgical outcomes in thyroid surgery” This is a meta-analysis of randomized controlled trials comparing drain vs no drain …

02/14/2026

Atypical Ductal Hyperplasia (ADH)

Atypical ductal hyperplasia (ADH): Is a benign proliferative breast lesion: Characterized by filling and distention of ducts by dysplastic monotonous epithelial cells: Forming architecturally compl…

02/11/2026

New Insights in HER2-Positive Advanced Breast Cancer: Validation of the HER2DX Genomic Test

A cutting-edge study published in npj Breast Cancer today reports validation of the HER2DX genomic test as a robust prognostic tool in first-line advanced HER2-positive breast cancer treated with t…

02/10/2026

Thyroid Awareness Month – Thyroid Lymphoma (Rare but Important)

Primary thyroid lymphoma is rare (

02/07/2026

Lobular Neoplasia

Lobular neoplasia: Is an atypical proliferation of small, dyscohesive epithelial cell: Within the terminal duct lobular unit (TDLU): That encompasses both: Atypical lobular hyperplasia (ALH) and lo…

02/04/2026

Untitled

New Research Alert: ER-Low Breast Cancer & Endocrine Therapy (2026) Liu et al. Breast Cancer Res Treat. Published Jan 6, 2026. 🔬 Key Focus This study evaluated outcomes and benefits of endocrine therapy (ET) in early breast cancer patients with low estrogen receptor (ER) expression (1%–10%) compared to ER-high and ER-negative cancers. 📊 Major Findings 🧬 ER-Low Phenotype Is Distinct ER-low (~4.4% of cases) behaves more like ER-negative disease in HER2-negative patients. Worse breast cancer-free survival compared to ER-high. Similar risk to triple-negative disease in HER2-negative subgroup. 💊 Endocrine Therapy Benefit Varies by Subtype…...

New Research Alert: ER-Low Breast Cancer & Endocrine Therapy (2026) Liu et al. Breast Cancer Res Treat. Published Jan 6, 2026. 🔬 Key Focus This study evaluated outcomes and benefits …

Address

Mount Sinai Medical Center 4306 Alton Road 2nd Floor
Miami Beach, FL
33140

Opening Hours

Monday	8:30am - 5pm
Tuesday	8:30am - 5pm
Wednesday	8:30am - 5pm
Thursday	8:30am - 5pm
Friday	8:30am - 5pm

Website

https://www.arrangoizmd.com/

Alerts

Be the first to know and let us send you an email when Rodrigo Arrangoiz MS, MD, FACS, FSSO posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Rodrigo Arrangoiz MS, MD, FACS, FSSO:

Shortcuts

Want your practice to be the top-listed Clinic in Miami Beach?

Who is Rodrigo Arrangoiz MS, MD, FACS? / Quien es Rodrigo Arrangoiz MD, MS, FACS

My name is Rodrigo Arrangoiz, I went to medical school at the Anahuac University in Mexico City, which is one of the most prestigious medical schools in Mexico:I graduated Suma Cum Laude from this medical school and was the president of the student medical council.

I trained in general surgery at Michigan State University where I was named chief resident during my fifth year of residency which was a great honor.

My complex surgical oncology fellowship which included head and neck training was performed at the Fox Chase Cancer Center in Philadelphia, Pennsylvania.

At the same time, I undertook a Masters in Science (Clinical Research for Health Care Professionals) at Drexel University in Philadelphia, Pennsylvania.

I also performed a two-year global online fellowship in Head and Neck Surgery and Oncology with the International Federations of Head and Neck Societies / Memorial Sloan Kettering Cancer Center.

I encountered patients with very complex problems, and the greatest lesson I learned was there are always treatment options, utilizing all different types of techniques including radiation, chemotherapy and surgery.

This comprehensive training has provided me with an extensive understanding of the multidisciplinary approach to treating patients with cancer.

I have developed a particularly strong interest in the surgical and multimodal treatment of patients with breast cancer, head and neck cancer (including thyroid and parathyroid cancer), and endocrine diseases (benign and malignant thyroid and parathyroid diseases), using traditional surgery, regional therapies, and minimally invasive techniques.

I am an expert in the treatment of thyroid cancer including; active surveillance for early, small papillary thyroid cancers, minimally invasive thyroid surgery, selective and comprehensive neck dissections.

For the management of parathyroid disease, I offer a minimally invasive radio-guided technique called MIRP (minimally invasive radio-guided parathyroidectomy) through a 2 cm incision which will allow the patient to have a great cosmetic result and quick return to normal life after the operation.

I am extremely aware of the impact that a breast cancer diagnosis has on a patient. I do my best to promote a positive atmosphere in which to start my patients' course of treatment and take the time to explain the pros and cons of each treatment option, so that they can make an informed decision.

My management philosophy also includes, not just an emphasis on successful treatment, but also preserving a good cosmetic outcome.

I feel fortunate to be a fellowship trained, very highly specialized clinician, because this combination of factors allows me, and our treatment team to focus on one thing all day, every day, and do it well: curing cancer. I think there is nothing more rewarding that I could do as a clinician.

I hold my patients as my number one priority. I will spend as much time as necessary educating, answering questions and providing guidance for each individual patient to help them throughout each stage of their management. I believe in honest discussions, where both the patients and family’s goals and expectations are openly communicated. We will work together as a team to put together an evidence based personalized treatment plan. My personal goal is to treat and care for every patient with the same compassion and honesty as if they were a friend or family member.

#Arrangoiz

Rodrigo Arrangoiz MS, MD, FACS es especialista en Cirugia de Mama / Cirugía de Tumores de Cabeza y Cuello / Cirugía Endocrina y Cirugía Oncológica compleja. Fue egresado como Médico General de la Universidad Anahuac Suma Cum Laude. Es miembro de Sociedad Quirúrgica S.C. que es el único grupo quirúrgico en México en donde todos los socios se entrenaron en las mejores instituciones académicas de los Estados Unidos de América. El Doctor Arrangoiz es experto en el manejo del Cáncer de Tiroides, Patología Quirúrgica de Tiroides, Hiperparatiroidismo Primario, Tumores de Cabeza y Cuello y Cáncer de Mama.

Fue entrenado en las mejores instituciones académicas de los Estados Unidos y mantiene certificaciones por los Consejos de Cirugía General y Cirugía Oncológica en México y en los Estados Unidos de América.

Su entrenamiento incluyó:

Cirugía General y Gastrointestinal - Michigan State University (2004 - 2010)

Cirugía Oncológica / Tumores de Cabeza y Cuello / Cirugía Endocrina - Fox Chase Cancer Center en Filadelfia (2010 al 2012)

Maestría en Ciencias (Clinical Research for Health Professionals) - Drexel University (Filadelfia) (2010 - 2012)

Cirugía de Tumores de Cabeza y Cuello / Cirugía Endocrina (2014 al 2016) - IFHNOS / Memorial Sloan Kettering Cancer Center

Ha participado en múltiples cursos y congresos como Conferencista y Profesor Invitado, así mismo ha realizado diversas publicaciones y artículos sobre temas relacionados con su especialidad. Se encuentra certificado por el Consejo Mexicano de Cirugía General y el Consejo Mexicano de Oncología así como es de los pocos mexicanos certificado por, el AMERICAN BOARD OF SURGERY, el cuál le faculta como cirujano con licencia en los EU.

Es miembro de diversas asociaciones médicas como el American College of Surgeons, American Thyroid Association, American Society of Endocrine Surgeons, American Medical Association, American Society of Clinical Oncology, Association of Academic Surgeons, Society of Surgical Oncology, The Society of Surgery of the Alimentary Tract, Society of American Gastrointestinal Endoscopic Surgeons, y la American Society of Breast Surgeons, entre otras.

Gracias a esto el Dr. Rodrigo Arrangoiz es reconocido como uno de los mejores especialistas en Cirugía de Tumores de Cabeza y Cuello / Cirugía Endocrina y Cirugía Oncológica en México, además de ser galardonado como uno de los 50 mejores médicos de México en los Top Doctors Awards 2018.

Rodrigo Arrangoiz MS, MD, FACS, FSSO

02/18/2026

02/18/2026

02/14/2026

02/14/2026

02/11/2026

02/10/2026

02/07/2026

02/04/2026

Address

Opening Hours

Website

Alerts

Contact The Practice

Shortcuts

Share

Category

Who is Rodrigo Arrangoiz MS, MD, FACS? / Quien es Rodrigo Arrangoiz MD, MS, FACS